New Lung Cancer Data May Offer Reprieve For Peregrine’s Bavituximab
This article was originally published in The Pink Sheet Daily
Executive Summary
Company releases new analysis of a Phase II second-line lung cancer study that resolves discrepancies that were holding back regulatory progress, now showing a 4.4 month overall survival benefit for first-in-class bavituximab. Peregrine is now gearing up for a Phase III study at the end of 2013.
You may also be interested in...
Peregrine Puts Positive Breast Cancer Trial Data Under Its Belt
Data for bavituximab in breast cancer merit further investigation, says company.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.